140 related articles for article (PubMed ID: 17822770)
21. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study.
Shen Y; Huang XJ; Wang JX; Jin J; Hu JD; Yu K; Wu DP; Wang SJ; Yu L; Chen XQ; Liu T; Liang YM; Chen FP; Li Y; Shen ZX
Int J Clin Pharmacol Ther; 2013 Sep; 51(9):738-45. PubMed ID: 23924680
[TBL] [Abstract][Full Text] [Related]
22. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.
Rosanova MT; Bes D; Serrano Aguilar P; Sberna N; Lede R
Infect Dis (Lond); 2018 Jul; 50(7):489-494. PubMed ID: 29262742
[TBL] [Abstract][Full Text] [Related]
24. Triazole antifungals: a review.
Peyton LR; Gallagher S; Hashemzadeh M
Drugs Today (Barc); 2015 Dec; 51(12):705-18. PubMed ID: 26798851
[TBL] [Abstract][Full Text] [Related]
25. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
[TBL] [Abstract][Full Text] [Related]
26. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
[TBL] [Abstract][Full Text] [Related]
27. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
28. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis.
Queiroz-Telles F; Goldani LZ; Schlamm HT; Goodrich JM; Espinel-Ingroff A; Shikanai-Yasuda MA
Clin Infect Dis; 2007 Dec; 45(11):1462-9. PubMed ID: 17990229
[TBL] [Abstract][Full Text] [Related]
29. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
30. Posaconazole exposure in critically ill ICU patients: a need for action.
König C; Göpfert M; Kluge S; Wichmann D
Infection; 2023 Dec; 51(6):1767-1772. PubMed ID: 37498488
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients.
Escamilla JE; January SE; Vazquez Guillamet R
Pathogens; 2023 May; 12(5):. PubMed ID: 37242364
[TBL] [Abstract][Full Text] [Related]
32. Antifungals: From Pharmacokinetics to Clinical Practice.
Carmo A; Rocha M; Pereirinha P; Tomé R; Costa E
Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237787
[TBL] [Abstract][Full Text] [Related]
33. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
34. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
35. Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies.
Zeng H; Wu Z; Yu B; Wang B; Wu C; Wu J; Lai J; Gao X; Chen J
BMC Cancer; 2021 Apr; 21(1):404. PubMed ID: 33853560
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
[TBL] [Abstract][Full Text] [Related]
37. Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study.
Tsutsumi I; Kunisawa S; Yoshida C; Seki M; Komeno T; Fushimi K; Morita S; Imanaka Y
Int J Clin Oncol; 2019 Nov; 24(11):1449-1458. PubMed ID: 31300904
[TBL] [Abstract][Full Text] [Related]
38. Health-care utilization and outcomes of patients at high risk of invasive fungal infection.
Fu R; Gundrum J; Sung AH
Clinicoecon Outcomes Res; 2018; 10():371-387. PubMed ID: 30034245
[TBL] [Abstract][Full Text] [Related]
39. Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.
Lee CH; Lin C; Ho CL; Lin JC
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866872
[TBL] [Abstract][Full Text] [Related]
40. Liver fungal infections: an overview of the etiology and epidemiology in patients affected or not affected by oncohematologic malignancies.
Fiore M; Cascella M; Bimonte S; Maraolo AE; Gentile I; Schiavone V; Pace MC
Infect Drug Resist; 2018; 11():177-186. PubMed ID: 29416363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
